MINDY1 promotes bladder cancer progression by stabilizing YAP

Abstract

Background Bladder cancer is one of the most commonly diagnosed urological malignant tumor. The Hippo tumor suppressor pathway is highly conserved in mammals and plays an important role in carcinogenesis. YAP is one of major key effectors of the Hippo pathway. However, the mechanism supporting abnormal YAP expression in bladder cancer remains to be characterized. Methods Western blot was used to measure the expression of MINDY1 and YAP, while the YAP target genes were measured by real-time PCR. CCK8 assay was used to detect the cell viability. The xeno-graft tumor model was used for in vivo study. Protein stability assay was used to detect YAP protein degradation. Immuno-precipitation assay was used to detect the interaction domain between MINDY1 and YAP. The ubiquitin-based Immuno-precipitation assays were used to detect the specific ubiquitination manner happened on YAP. Results In the present study, we identified MINDY1, a DUB enzyme in the motif interacting with ubiquitin-containing novel DUB family, as a bona fide deubiquitylase of YAP in bladder cancer. MINDY1 was shown to interact with, deubiquitylate, and stabilize YAP in a deubiquitylation activity-dependent manner. MINDY1 depletion significantly decreased bladder cancer cell proliferation. The effects induced by MINDY1 depletion could be rescued by further YAP overexpression. Depletion of MINDY1 decreased the YAP protein level and the expression of YAP/TEAD target genes in bladder cancer, including CTGF, ANKRD1 and CYR61. Conclusion In general, our findings establish a previously undocumented catalytic role for MINDY1 as a deubiquitinating enzyme of YAP and provides a possible target for the therapy of bladder cancer.

Characterizing isoform switching events in esophageal adenocarcinoma

“…50 In BE and EAC, MINDY1 was identified in a set of 90 genes significantly predicting disease progression by distinguishing EAC progressors from patients with non-dysplastic BE. 51 Moreover, MINDY-1 was found to promote bladder cancer progression by stabilizing YAP, 52 a key tumorigenesis pathway member that can also be induced by conjugated bile acids in EAC. 53 In our analysis, increased usage of the MINDY1 transcript that lacks deubiquitinase (DUB) domains and a decreased usage of the MINDY1 transcript that contains five DUB domains are observed, potentially suggesting impaired MINDY-1 function during EAC progression.…”

NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation

“…Co-immunoprecipitation (Co-IP) was performed as described in a previous study [ 23 ]. The cells were lysed in lysis buffer (Aspen Biological) and approximately 200 μg of total cellular proteins were incubated overnight with target antibody at 4 °C followed by the addition of 20 μL of protein A agarose beads (#1614813, BIO-RAD).…”

The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment

“…While there is limited work examining the role of YAP in BCa recurrence, a study by Ghasemi et al reported higher YAP expression in recurrent BCa [ 110 ]. There is additional work looking more broadly at agents that modulate BCa progression through YAP [ 111 , 112 ] and at molecules, including miRNAs, that affect BCa development through YAP [ 113 , 114 ]. YAP is also involved in BCa chemoresistance, with studies examining the naturally-derived ailanthone as an inhibitor of proliferation and migration in cisplatin-resistant BCa cells through YAP and Nrf2 repression [ 115 , 116 ].…”